StratifiCare Inc (StratifiCare) is a developer and manufacturer of in vitro diagnostic (IVD) assay solutions. The company is evaluating severe dengue prediction test kit which utilizes a set of biomarkers and a laboratory assay platform to identify the risk of severe dengue in patients. Its tests enable healthcare providers and physicians to deliver customized therapies. StratifiCare works in partnership with National University Hospital, Ng Teng Fong General Hospital, Tan Tock Seng Hospital, BDS Foundation and other companies. The company is a spin-off from the National University of Singapore. StratifiCare is headquartered in Singapore City, Singapore.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company StratifiCare Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- StratifiCare Inc Company Overview
- StratifiCare Inc Company Snapshot
- StratifiCare Inc Pipeline Products and Ongoing Clinical Trials Overview
- StratifiCare Inc - Pipeline Analysis Overview
- StratifiCare Inc - Key Facts
- StratifiCare Inc - Major Products and Services
- StratifiCare Inc Pipeline Products by Development Stage
- StratifiCare Inc Pipeline Products Overview
- StratifiDen
- StratifiDen Product Overview
- Stratifiden Dengue Prognostic Kit
- Stratifiden Dengue Prognostic Kit Product Overview
- StratifiREY
- StratifiREY Product Overview
- StratifiCare Inc - Key Competitors
- StratifiCare Inc - Key Employees
- StratifiCare Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- StratifiCare Inc, Recent Developments
- Nov 02, 2020: StratifiCare receives recognition for world’s first severe Dengue prediction test
- Oct 16, 2020: Mitsubishi Electric - StratifiCare collaboration featured on Nikkei Business
- Dec 11, 2019: Mexican Society of Public Health (SMSP) signs MoU with StratifiCare to study effectiveness of Dengue prognostic test in Mexico
- Apr 24, 2019: StratifiDen™ Dengue Prognostic Test reduces unnecessary hospitalization and social burden
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- StratifiCare Inc Pipeline Products and Ongoing Clinical Trials Overview
- StratifiCare Inc Pipeline Products by Equipment Type
- StratifiCare Inc Pipeline Products by Indication
- StratifiCare Inc, Key Facts
- StratifiCare Inc, Major Products and Services
- StratifiCare Inc Number of Pipeline Products by Development Stage
- StratifiCare Inc Pipeline Products Summary by Development Stage
- StratifiDen - Product Status
- StratifiDen - Product Description
- Stratifiden Dengue Prognostic Kit - Product Status
- Stratifiden Dengue Prognostic Kit - Product Description
- StratifiREY - Product Status
- StratifiREY - Product Description
- StratifiCare Inc, Key Employees
- Glossary
- StratifiCare Inc Pipeline Products by Equipment Type
- StratifiCare Inc Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Veltest Biotech Pte Ltd
- Institute of Bioengineering and Nanotechnology
- Biomedix Singapore Pte Ltd